Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs

Tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor (EGFR) are the standard of care treatment in non-small cell lung cancer (NSCLC). TKIs are used first line in EGFR mutation-positive NSCLC; erlotinib is the only TKI approved for subsequent lines of treatment in EGFR wild-...

Full description

Saved in:
Bibliographic Details
Main Authors: Melosky, Barbara, Hirsh, Vera
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2014
Subjects:
Oncology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4165207/
https://ncbi.nlm.nih.gov/pubmed/25279350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2014.00238
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items